Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (845)	2/27/2001 12:51:40 AM
From: scaram(o)uche	Respond to of 1475

I had missed this patent. This could be pretty cool. I always thought that hyperacute rejection was a weakness of BTRN's, and that Imutran/Sandoz complementation was an absolute necessity. Don't know the significance of this one yet, caught off guard. But..... looks good......... US6153428:.alpha.(1,3) galactosyltransferase negative porcine cells Inventor(s): Gustafsson; Kenth T. , Amersham, United Kingdom Sachs; David H. , Newton, MA Applicant(s): BioTransplant, Inc., Charlestown, MA News, Profiles, Stocks and More about this company Issued/Filed Dates: Nov. 28, 2000 / March 26, 1996 Abstract: : Transgenic swine in which the normal expression of .alpha.(1,3) galactosyltransferase is prevented in at least one organ of tissue type. The absence or inactivation of this enzyme prevents the production of carbohydrate moieties having the distinctive terminal Gal.alpha.1-3Gal?-4GlcNAc epitope that is a significant factor in xenogeneic, particularly human, transplant rejection of swine grafts.

To: tuck who wrote (845)	2/27/2001 1:29:31 AM
From: scaram(o)uche	Respond to of 1475

>> We await your post-listening opinion. << Not bad! I'm mellowing a bit on Eligix. Had a good conversation with a friend who is close to this stuff today. Pointed out that the BMT registry says that 18,000 procedures are performed each year for B cell malignancies. It's still a question, of course, if 4 logs of purification will be enough. But..... I'm surprised at how many procedures are done for this indication, and I eat my earlier words. Not difficult, at all, to see how they arrived at a figure of $150M for the EXISTING market. And, regarding my second point...... that a little donor T cell contamination helps to condition the host.... I was referring to studies where there was global T cell depletion of donor marrow. The Eligix procedure removes only CD8-positive cells. So..... guess it would be a good idea to wait for data before popping mouth off?